CVID: Trading a Monthly Hospital Day for a Weekly Kitchen-Table Infusion
A small-business owner with common variable immunodeficiency wants off the hospital's infusion schedule. Nothing about her antibody deficiency has changed — only whether she is willing to keep losing a full day of work every four weeks to get the same protection.
Yolanda P., 35, owns a small catering business she built from nothing over the past nine years, work that means fourteen-hour days around weddings and holidays but almost never a predictable Tuesday. She was diagnosed with common variable immunodeficiency at twenty-eight after a year of unexplained sinus infections and one hospitalization for pneumonia, and has been on monthly hospital-based IVIG for the seven years since — stable, infection-free, but with each infusion requiring a full day away from her business that she has never been able to fully hand off to her small staff. She has no other chronic medical conditions and has never had a reaction to an IVIG infusion requiring the infusion to be stopped or slowed.
What brought today's conversation wasn't a change in her antibody levels or her infection frequency — both remain excellent — but a pattern she's noticed and finally mentioned: a week of fatigue and low-grade malaise reliably arriving before each month's infusion, improving within a day of the next one. That "wear-off" pattern is a recognized consequence of IVIG's peak-trough pharmacokinetics, where serum IgG spikes immediately post-infusion and drifts down over the following weeks before the next dose restores it. Abolhassani et al., 2012, Journal of Clinical Immunology, pooled forty-seven studies and 1,484 compared cases and found subcutaneous immunoglobulin achieves comparable IgG troughs with fewer adverse events, better health-related quality of life, and higher treatment satisfaction than hospital-based IVIG — largely attributed to home administration and a flatter, more stable absorption curve rather than the same monthly peak-and-decline. The least-quoted finding in that same review is the one that actually describes her: patients on the subcutaneous route recovered function faster and lost less time off work. For a woman whose business cannot absorb a missing Tuesday, that endpoint is not a lifestyle preference sitting politely beside the clinical data — it is the clinical data reaching the thing she came in to talk about.
Matching the mechanism to her actual complaint
Her labs and infection history give us no clinical reason to keep her on the same modality if a better-fitting one exists. Abolhassani and colleagues pooled forty-seven studies and found SCIG achieves comparable troughs with fewer adverse events and meaningfully better quality-of-life scores than hospital IVIG. I'd support switching her to home subcutaneous therapy.
You're right that the pooled data favors SCIG on trough stability and quality of life — I'm not disputing Abolhassani's numbers. What I want on record is that this isn't a trivial switch for every patient: home self-infusion requires real training, and losing supervised monitoring means a missed dose or a site reaction could go unnoticed longer than it would here. That said, Yolanda has no dexterity or vision limitations and has already told us she's motivated to learn it, which puts her in the group most studies show does well with the transition.
The literature's average outcome doesn't automatically transfer to any given patient — it matters that her specific circumstances actually match the profile that literature describes doing well.
Her specific complaint is worth naming directly, because it isn't just a general preference for convenience — the pre-infusion fatigue she's describing is a recognized consequence of IVIG's peak-trough swing, and SCIG's weekly, flatter absorption curve is mechanistically suited to reducing exactly that symptom, not just the inconvenience of the hospital day. Given that her circumstances also match the profile associated with successful home training, I'd move forward with the switch and a structured training period rather than treat this as a purely lifestyle decision.
Yolanda completed a two-session training program and transitioned to weekly home SCIG over the following month. Her pre-infusion fatigue pattern resolved within the first six weeks, and her trough IgG on the new regimen has remained comparable to her prior hospital-based levels.
Agreed by all three: the switch resolved cleanly because her individual circumstances matched the profile the literature describes doing well with home therapy — not because SCIG is uniformly the better choice for every CVID patient on IVIG, a distinction the team noted explicitly for her chart in case the question comes up again for a different patient.